Connect with us

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment



Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of positive developments in recent weeks.

After a recent spike higher, the stock faces immediate resistance at the $0.63 level as part of the bounce-back play. A rally followed by a close above the $0.63 level should open the door for the stock to make a run for the $0.77 mark, the next substantial resistance level.

The stock rising and finding support above the $0.77 mark should bring to an end the sell-off wave that had plunged the stock to all-time lows. Conversely, failure to take out the $0.63 level could leave the stock susceptible to further drops in continuation of the long-term bear trend.

About Helix TCS stock

Helix TCS casts itself as a leading provider of crucial infrastructure and technology that helps licensed cannabis businesses stay competitive in the multi-billion-dollar industry. The company boasts of an array of proprietary technology and security services used in enhancing supply management as well as asset protection. The company’s solutions are currently in use in over 2,000 customer locations in 38 states across the U.S and six countries.

BioTrack System Boost

Helix TCS sentiments and prospects have edged higher in the market on the confirmation that its proprietary BioTrack traceability system used in adult-use marijuana sales has processed over $11 million worth of sales.

On its first day of use in the state of Illinois, the system processed over $3.2 million in transactions with the numbers expected to continue increasing as the state continues to issue more licenses. The BioTrack system is designed to provide licensed cannabis operators a platform for managing business and maintaining compliance.

Digital Payment Opportunity

Likewise, Helix TCS has inked a partnership with Alt Thirty Six to enable digital payment payments in-store as well as online and on delivery services. The partnership will allow thousands of cannabis dispensaries across the U.S to accept digital payments consequently alleviate the risk of dealing with cash and credit cards.

“The primary mission of Helix Technologies is to be the leading provider of critical infrastructure services in the cannabis industry. By partnering with Alt Thirty-Six, we are able to provide our dispensary partners with yet another tool to help them run an efficient and compliant business,” said Moe Afaneh, COO at Helix BioTrack.

The unveiling of the BioTrack system in Illinois comes hot on the heels of the company launching an integrated hemp-tracking module in Delaware. The system allows operators to import hemp derivatives into medical cannabis products consequently ensuring patients get exactly what they asked for.

Bottom Line

The tide is slowly turning in favor of Helix TCS stock after coming under immense pressure in 2019. Improved operational efficiency with the launch of the BioTrack system is one of the key developments that continues to shape the company’s prospects.

Strategic acquisitions, as well as an increased focus on the customer and targeted internal improvements, should continue to drive growth and consequently shareholder value going forward. Improving fundamentals and positive developments provide clear evidence of positive trend materializing. In our view, Helix TCS stock looks set to continue bottoming out from current lows

We will be updating our subscribers as soon as we know more. For the latest updates on Helix TCS stock, sign up below!

Disclosure: We have no position in Helix TCS stock and have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Stocks

Why Lexaria Bioscience Corp (OTCMKTS:LXRP) Is A Comeback Play



Lexaria Bioscience

Lexaria Bioscience Corp (OTCMKTS:LXRP) brightest days lie ahead. The sentiments shared by Chief Executive Officer, Chris Bunka, are slowly coming to fruition, going by recent price action activity. After a steep pullback in 2019, the stock has once again started climbing higher, as investors react to milestones achieved in 2019 that affirm long-term prospects.

Lexaria Bioscience Catalysts and Price Analysis

A confirmation that the global innovator in drug delivery systems achieved almost everything it set out to accomplish in 2019 continues to strengthen market sentiments. The inking of strategic partnerships with Fortune 500 style companies is another development that the management continues to tout.

Likewise, Lexaria Bioscience succeeded in getting its DehydraTECH technology to market, consequently creating an avenue for generating long-term value. The company’s Intellectual Property strategy has also started to pay dividends, affirming what is at stake going forward. Reports that the company is already experiencing an increase in revenues is another catalyst that continues to shore the stock’s sentiments and prospects in the markets.

Lexaria Bioscience has already started bottoming out from all-time lows in what appears to be the development of a positive trend. A 10% plus rally from one-year lows continue to fuel optimism that the stock has clocked a bottom and due for a correction higher.

Standing in the way of the emerging uptrend is the $0.50 mark, which is the immediate short-term resistance level. A rally followed by a close above the…

Continue Reading

Featured Stocks

Why OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Is A Promising Stock In 2020



OWC Pharmaceutical Research

In 2020, investors are looking for cannabis stocks that can deliver excellent returns following a disappointing 2019, which saw many pot stocks crash to multiyear lows. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) stands out as a promising cannabis stock to own in 2020.

About OWC Pharmaceutical Research

The cannabis stock universe is vast, so for investors who may have just come across OWC Pharmaceutical for the first time an introduction of the company is in order.

OWC Pharmaceutical is an Israel-based cannabis research company. It is focused on research and development of cannabis-based medical products. The company’s work currently includes development of cannabis-based treatments for a variety of diseases and disorders such as multiple myeloma, psoriasis and fibromyalgia.

Moreover, OWC Pharmaceutical provides consulting services to both government and private entities in the field of medical cannabis programs.

OWC Pharmaceutical Research exited 2019 on a high note

While 2019 ended up being one of the toughest year for cannabis stocks, OWC Pharmaceutical had strong finish to the year. The stock gained 35% on December 31. Before that, the stock rose 65% on December 30. The back-to-back gains in the final days of 2019 helped OWC Pharmaceutical cut its losses for the year but also signaled improving investor sentiment on the stock heading into the new year.

OWC Pharmaceutical finished 2019 at $0.089, having pulled from a low of $0.0045 at the beginning of December.


Continue Reading

Featured Stocks

Planet 13 Stock (CNSX:PLTH) (OTCMKTS:PLNHF): Is It A Buy Or Sell?



Planet 13 stock

The marijuana stocks universe presents a variety of choices. But not all choices are great. You want to put your money in a marijuana company with a strong competitive advantage, great growth potential, and solid financials. If you are looking for a great pot stock to buy heading into 2020, Planet 13 stock (CNSX:PLTH) (OTCMKTS:PLNHF) is a strong candidate.

About Planet 13 stock

For investors who may be learning about Planet 13 Holdings for the first time, this is a vertically-integrated marijuana business. It is one of the leading marijuana companies in the Nevada market. Planet 13 Holdings is engaged in the cultivation, processing, and retail of marijuana products and it already has several marijuana brands to its credit. It operates the largest marijuana retail outlet in the world.

What you should know about Planet 13 stock

For marijuana sector in general, 2019 has generally been a rough year. Many marijuana stocks have dropped to multiyear lows. As the charts show, Planet 13 Holdings stock has been through a lot of ups and downs this year. Still, those swings have delivered decent returns for investors who know how to play stocks like Planet 13 Holdings in volatile periods.

Presently, Planet 13 Holdings stock is trading at $1.64. The stock began the year at $1.00. It jumped to $1.64 in February, thereby returning nearly 65% in space of a few weeks. There was a…

Continue Reading

MJ Stocks